Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979 | 0.96 | — | — | |
| SCHEMBL4727402 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| SCHEMBL3210302 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Bromide SCHEMBL1999327 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Fluoride SCHEMBL1025918 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Ammonia Solution, Strong SCHEMBL6136995 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Fluoride SCHEMBL73856 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Dimethylamine SCHEMBL6889985 | 0.90 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL4787789 | 0.86 | ALDH1A1 (0.39) | ALDH1A1 | |
| Trimethylammonium SCHEMBL4940105 | 0.86 | ALDH1A1 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260092-B | Synthesis method of 2-chloronicotinamide and N-substituted derivative thereof | 山东京博生物科技有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-115260092-A | Synthesis method of 2-chloronicotinamide and N-substituted derivative thereof | 山东京博生物科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-108101799-A | A kind of high-efficient production technology of glycine | 严世佳 | 2018-06-01 | — | — | CN | claimed |
| EP-2920156-B9 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | GUERBET SA (FR) | 2017-04-19 | — | — | EP | claimed |
| EP-2920156-B1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | GUERBET SA (FR) | 2016-12-07 | — | — | EP | claimed |
| CN-1196684-C | Process for producing N.N'-carbonyl dilactan | SNPC (FR) | 2005-04-13 | — | — | CN | claimed |
| US-6699988-B2 | BY REACTING PHOSGENE AND LACTAM IN THE PRESENCE OF A NON-NUCLEOPHILIC ALIPHATIC TERTIARY AMINE, SUCH AS N,N-DIISOPROPYLETHYLAMINE; HIGH PURITY, GOOD YIELDS | SNPE (FR) | 2004-03-02 | — | — | US | claimed |
| US-20010044532-A1 | Process for the preparation of N,N' -carbonylbislactams | ISOCHEM (FR) | 2001-11-22 | — | — | US | claimed |
| CN-1322718-A | Preparation method of N, N' -carbonyl dilactan | SNPC (FR) | 2001-11-21 | — | — | CN | claimed |
| EP-3702393-B1 | PRODUCTION METHOD FOR LOW INCLUSION RATE POLYROTAXANE | ASM INC (JP) | 2025-01-15 | — | — | EP | disclosed |
| CN-115611806-B | Preparation method of 4-trifluoromethyl-3-cyanopyridine | 江苏中旗科技股份有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-111479819-B | Method for preparing peptide and method for treating alkali | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-115636851-B | Preparation method of mono-alkoxy substituted pentafluoro-cyclotriphosphazene | 云南云天化股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-115636851-B | Preparation method of mono-alkoxy substituted pentafluoro-cyclotriphosphazene | 云南云天化股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-4774256-A | MERCAPTO AND ACYLMERCAPTO AMIDES | E. R. SQUIBB & SONS, INC. (US) | 1988-09-27 | — | — | US | disclosed |
| US-4722810-A | Enkephalinase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1988-02-02 | — | — | US | disclosed |
| EP-0136883-B1 | ENKEPHALINASE INHIBITORS | E.R. Squibb & Sons, Inc. (US) | 1987-11-25 | — | — | EP | disclosed |
| EP-0161769-B1 | ENKEPHALINASE INHIBITORS | E.R. Squibb & Sons, Inc. (US) | 1987-10-28 | — | — | EP | disclosed |
| EP-0161769-A1 | Enkephalinase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1985-11-21 | — | — | EP | disclosed |
| EP-0136883-A2 | Enkephalinase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044532-A1 | Process for the preparation of N,N' -carbonylbislactams | BPGM, COASY, NANS | ALDH1A1 3080/4885TAAR1 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.